Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 35
Filter
Add more filters










Publication year range
1.
Nitric Oxide ; 78: 72-80, 2018 08 01.
Article in English | MEDLINE | ID: mdl-29859918

ABSTRACT

Nitric oxide (NO)-sensitive soluble guanylyl cyclase (sGC), an enzyme that catalyzes the conversion of guanosine-5'-triphosphate (GTP) to cyclic guanosine-3',5'-monophophate (cGMP), transduces many of the physiological effects of the gasotransmitter NO. Upon binding of NO to the prosthetic heme group of sGC, a conformational change occurs, resulting in enzymatic activation and increased production of cGMP. cGMP modulates several downstream cellular and physiological responses, including but not limited to vasodilation. Impairment of this signaling system and altered NO-cGMP homeostasis have been implicated in cardiovascular, pulmonary, renal, gastrointestinal, central nervous system, and hepatic pathologies. sGC stimulators, small molecule drugs that synergistically increase sGC enzyme activity with NO, have shown great potential to treat a variety of diseases via modulation of NO-sGC-cGMP signaling. Here, we give an overview of novel, orally available sGC stimulators that Ironwood Pharmaceuticals is developing. We outline the non-clinical and clinical studies, highlighting pharmacological and pharmacokinetic (PK) profiles, including pharmacodynamic (PD) effects, and efficacy in a variety of disease models.


Subject(s)
Enzyme Activators/therapeutic use , Soluble Guanylyl Cyclase/metabolism , Administration, Oral , Animals , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/pharmacokinetics , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Clinical Trials as Topic , Drug Discovery , Enzyme Activation/drug effects , Enzyme Activators/administration & dosage , Enzyme Activators/pharmacokinetics , Enzyme Activators/pharmacology , Fibrosis/drug therapy , Humans , Signal Transduction/drug effects
2.
J Anim Sci ; 76(7): 1838-48, 1998 Jul.
Article in English | MEDLINE | ID: mdl-9690639

ABSTRACT

The presence of alpha2-adrenoceptors in membranes from omental and s.c. adipose tissue from gilts and barrows was shown in saturation binding assays with [3H]yohimbine. Four trials tested effects of alpha2-adrenoceptor antagonists (A2AA) on plasma concentrations of NEFA and urea nitrogen (PUN). In Trial 1, barrows were given i.v. injections of saline, 200 microg/kg BW of one of three A2AA (efaroxan, idazoxan, or RX821002), or 25 microg/kg BW of isoproterenol. Concentrations of NEFA were measured in plasma harvested every 15 min from 1 h before to 2 h after treatment. Compared with results for saline-treated pigs, areas under the curve (AUC) for NEFA were increased (P < .05) by efaroxan, RX821002, and isoproterenol. In Trial 2, barrows received i.v. doses of saline, efaroxan (200 or 400 microg/kg BW), or RX821002 (200 or 400 microg/kg BW). Levels of NEFA were quantified in plasma obtained at 15-min intervals through 2 h after treatment. Among pigs treated with RX821002 at 400 microg/kg BW, mean NEFA AUC was more than three times greater (P < .05) than that for saline-treated animals. Trial 3 tested whether NEFA responses to A2AA were due to direct effects on alpha2-receptors or involved beta-adrenoceptor mediation. Pigs were first treated i.v. with saline or propranolol (1 mg/kg BW). One hour later, pigs were treated i.v. with RX821002 (400 microg/kg BW) or the beta-adrenoceptor agonist cimaterol (25 microg/kg BW). Compared to values for pigs treated with saline at both injections, NEFA AUC among pigs treated with saline at the first injection and RX821002 at the second doubled (P > .05). Plasma NEFA AUC among pigs treated with saline then cimaterol rose nearly fourfold (P < .05) compared with saline-treated controls. Mean NEFA AUC among propranolol-treated pigs was similar to values for saline-treated pigs, suggesting beta-adrenoceptor involvement in the effect of A2AA on NEFA. In Trial 4, pigs were treated s.c. 10 times at 8-h intervals with saline, RX821002 (400 microg/[kg BW x injection]), cimaterol (20 microg/[kg BW x injection]) or recombinant porcine somatotropin (rpST; 1 mg/[pig-injection]). After the 10th treatment, only cimaterol increased NEFA AUC compared to saline-treated controls (P < .05). Mean PUN AUC was reduced by RX821002 and rpST compared to controls; PUN among rpST-treated pigs was lower than that among RX821002-treated pigs (P < .05). In summary, A2AA increase lipolysis in swine by potentiating lipolytic effects of endogenous catecholamines on beta-adrenoceptors. Reduced PUN suggests improved nitrogen efficiency may result from treatment with A2AA.


Subject(s)
Adrenergic alpha-2 Receptor Antagonists , Adrenergic alpha-Antagonists/pharmacology , Blood Urea Nitrogen , Fatty Acids, Nonesterified/blood , Swine/metabolism , Adrenergic beta-Agonists/pharmacology , Animals , Area Under Curve , Benzofurans/pharmacology , Female , Idazoxan/analogs & derivatives , Idazoxan/pharmacology , Imidazoles/pharmacology , Isoproterenol/pharmacology , Male , Random Allocation
3.
J Anim Sci ; 76(7): 1849-58, 1998 Jul.
Article in English | MEDLINE | ID: mdl-9690640

ABSTRACT

We studied the effects of alpha2-adrenoceptor antagonists (A2AA) on nitrogen (N) partitioning. The diets fed contained 19.8% CP and 1.15% lysine. Pigs were fed the diet as a percentage of BW equaling approximately 90% of voluntary intake. In Trial 1, pigs (n = 11/treatment) were fed a basal diet and injected s.c. at 8-h intervals for 11 d with saline, RX821002 (25 mg/injection), or cimaterol (.6 mg/injection). Compared to saline-treated pigs, urinary N, as a percentage of N eaten, decreased among pigs injected with RX821002 (15%, P < .05) or cimaterol (17%, P < .05). In Trial 2, pigs got saline (n = 6) or 25 mg RX821002 (n = 6) as s.c. injections three times daily, or they were fed a diet containing 150 ppm RX821002 and injected thrice daily with saline (n = 6) for 11 d. The RX821002 lowered apparent DM and N digestibility (P < .05). Compared to controls, RX821002 lowered urinary N, as a percentage of N eaten, 15 and 18% when given by injections or per os, respectively, but effects were not significant. Trial 3 evaluated the effects of RX821002 fed at levels of 0 (n = 6), 37.5 (n = 5), 75 (n = 6), or 150 ppm (n = 6). Contrasts showed linear dose-dependent decreases in gain and apparent N digestibility (P < .05). Compared to untreated controls, urinary N, expressed as a percentage of N consumed, decreased 2, 12, and 10% among pigs fed diets with 37.5, 75, or 150 ppm RX821002, respectively, but effects were not significant. Trial 4 compared N balance in pigs (n = 6/treatment) fed basal diet or diet with 100 ppm RX821002 to that of pigs fed diets with 25 or 100 ppm yohimbine. Treatments reduced apparent N and DM digestibility (P < .05). Urinary N, as a percentage of N consumed, decreased 16 (P > .05), 18 (P < .05), and 24% (P < .05) for 100 ppm RX821002, 25 ppm yohimbine, or 100 ppm yohimbine, respectively. Data from Trials 2, 3, and 4 from control pigs (n = 18) or pigs fed A2AA (all A2AA sources and doses; n = 41) were pooled and analyzed. Feeding A2AA decreased apparent N and DM digestibility (P < .01). The fact that fecal moisture content was higher in pigs fed A2AA suggests rate of digesta passage increased and offers an explanation for reduced N and DM digestibility in treated pigs. Despite adverse effects of A2AA, efficiency of postabsorptive N metabolism increased. As a percentage of N consumed and compared to control pigs, urinary N decreased 15% (P < .01) and retained N increased 12% (P < .05) in animals fed A2AA. Data from these studies show net efficiency of N metabolism is improved in swine given A2AA.


Subject(s)
Adrenergic alpha-2 Receptor Antagonists , Adrenergic alpha-Antagonists/pharmacology , Idazoxan/analogs & derivatives , Nitrogen/metabolism , Swine/metabolism , Administration, Oral , Adrenergic alpha-1 Receptor Antagonists , Adrenergic alpha-Antagonists/administration & dosage , Adrenergic beta-Agonists/pharmacology , Animal Feed , Animals , Digestion/drug effects , Dose-Response Relationship, Drug , Ethanolamines/administration & dosage , Ethanolamines/pharmacology , Idazoxan/administration & dosage , Idazoxan/pharmacology , Injections, Subcutaneous/veterinary , Linear Models , Male , Nitrogen/urine , Random Allocation , Yohimbine/administration & dosage , Yohimbine/pharmacology
4.
Mol Endocrinol ; 11(7): 859-66, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9178746

ABSTRACT

Somatostatin (SRIF) was discovered as an inhibitor of GH secretion from pituitary somatotroph cells. SRIF analogs are very effective agents used to treat neuroendocrine tumors and are now being used with increasing frequency in clinical trials to treat more aggressive malignancies. However, the cellular components mediating SRIF signal transduction remain largely unknown. We have stably overexpressed the SRIF type 2 receptor (SST2) in GH4 rat somatomammotroph cells, establishing a physiologically relevant model system. In this model, the SRIF analog, BIM23014, inhibited forskolin-induced cAMP accumulation, protein kinase A activation, cAMP response element-binding protein phosphorylation, and Pit-1/GHF-1 promoter activation in an okadaic acid-insensitive manner. Pertussis toxin inhibited the effects of BIM23014, documenting that SST2 signaling was coupled to Gi. Moreover, the inhibitory effects of BIM23014 were reversed by overexpression of protein kinase A catalytic subunit, indicating that SRIF does not act via serine/threonine phosphatases, but, rather, by lowering protein kinase A activity. These data define the components of the SRIF/SST2 receptor signaling pathway and provide important mechanistic insights into how SRIF controls neuroendocrine tumors. As SRIF analogs are effective antitumor agents, and many other related compounds are in development, the knowledge gained here will further our understanding of their mechanism of action in other malignancies as well.


Subject(s)
Antineoplastic Agents/pharmacology , Cyclic AMP Response Element-Binding Protein/genetics , Cyclic AMP Response Element-Binding Protein/metabolism , Cyclic AMP-Dependent Protein Kinases/metabolism , Peptides, Cyclic/pharmacology , Somatostatin/analogs & derivatives , Somatostatin/pharmacology , Transcription, Genetic/drug effects , Animals , Colforsin/pharmacology , Cyclic AMP Response Element-Binding Protein/drug effects , Cyclic AMP-Dependent Protein Kinases/drug effects , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , Okadaic Acid/pharmacology , Phosphorylation/drug effects , Promoter Regions, Genetic/drug effects , Promoter Regions, Genetic/physiology , RNA, Messenger/analysis , RNA, Messenger/genetics , Rats , Signal Transduction/drug effects , Transcription, Genetic/genetics
5.
Mol Pharmacol ; 50(4): 709-15, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8863814

ABSTRACT

The study of the five somatostatin receptor subtypes (SSTx, where x is the subtype number) has been hampered by the lack of high affinity antagonists. Potent and selective antagonists would increase our understanding of SST structure, function, and regulation. In this study, the identification of novel disulfide-linked cyclic octapeptide antagonists of somatostatin is described. The antagonists contain a core structure of a DL-cysteine pair at positions 2 and 7 of the peptides. Substitution of a D-cysteine at position 2 with an L-cysteine converts the full antagonist into a full agonist. All somatostatin receptor subtypes are coupled to inhibition of adenylate cyclase. The functional properties of these peptides have been determined in radioligand binding assays, in functional coupling of the SST2 subtype to yeast pheromone response pathway, and in cAMP accumulations. One peptide antagonist [Ac-4-NO2-Phe-c(D-Cys-Tyr-D-Trp-Lys-Thr-Cys)-D-Tyr-NH2] displays a binding affinity to SST2 comparable with that observed for the native hormone (Ki = 0.2 nM) and reverses somatostatin-mediated inhibition of cAMP accumulation in rat somatomammotroph GH4C1 cells, cells transfected with the SST2 and SST5 subtypes, as well as somatostatin-stimulated growth of yeast cells expressing the SST2 subtype. This class of somatostatin antagonists, which are the first to be described, should be useful for determination of somatostatin's diverse functions in vivo and in vitro.


Subject(s)
Somatostatin/analogs & derivatives , Somatostatin/antagonists & inhibitors , Amino Acid Sequence , Animals , Binding, Competitive , Cyclic AMP/metabolism , Iodine Radioisotopes , Peptides/metabolism , Peptides/pharmacology , Radioligand Assay , Rats , Receptors, Somatostatin/antagonists & inhibitors , Receptors, Somatostatin/metabolism , Saccharomyces cerevisiae/drug effects
6.
Mol Pharmacol ; 50(4): 829-37, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8863827

ABSTRACT

The rat A2a adenosine receptor, a G protein-coupled receptor, was functionally expressed in the yeast Saccharomyces cerevisiae. High affinity binding sites for A2a adenosine agonists were detected in yeast membranes containing the endogenous Grx protein Gpa1. Agonist saturation binding isotherms using [3H]5'-N-ethylcarboxamidoadenosine indicated that the A2a adenosine receptor expressed in yeast cell membranes displays pharmacological properties equivalent to those observed when the receptor is expressed in human embryonic kidney 293 cell membranes. The rank order of potency of various agonists in [3H]5'-N-ethylcarboxamidoadenosine competition binding assays performed with yeast cell membranes was comparable to that seen for the receptor expressed in mammalian cell membranes. Adenosine agonist-dependent growth response of yeast strains expressing the A2a adenosine receptor was elicited via activation of the yeast pheromone-response pathway. Induction of a pheromone-responsive FUS1-HIS3 reporter gene in far1 his3 cells permits cell growth in medium lacking histidine. The sensitivity of the bioassay was increased by deletion of the STE2 gene, which encodes the yeast alpha-mating pheromone receptor. The growth response was dose dependent, and agonists of varying affinities displayed a rank order of potency comparable to that observed in competition binding assays. Agonist-activated growth assays performed in liquid culture gave ED50 values for various adenosine agonists consistent with reported Kd alpha values. Yeast strains expressing a single receptor/G protein complex will be useful as a model system for the study of receptor/G protein interactions in vivo.


Subject(s)
Pheromones/physiology , Receptors, Purinergic P1/physiology , Adenosine/analogs & derivatives , Adenosine/metabolism , Adenosine/pharmacology , Adenosine-5'-(N-ethylcarboxamide) , Animals , Cells, Cultured , GTP-Binding Proteins/metabolism , GTP-Binding Proteins/physiology , Humans , Kidney/physiology , Kinetics , Phenethylamines/metabolism , Phenethylamines/pharmacology , Pheromones/metabolism , Purinergic P1 Receptor Agonists , Rats , Receptors, Purinergic P1/metabolism , Receptors, Somatostatin/metabolism , Receptors, Somatostatin/physiology , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae/metabolism , Tritium
7.
Mol Cell Biol ; 15(11): 6188-95, 1995 Nov.
Article in English | MEDLINE | ID: mdl-7565771

ABSTRACT

A detailed analysis of structural and functional aspects of G-protein-coupled receptors, as well as discovery of novel pharmacophores that exert their effects on members of this class of receptors, will be facilitated by development of a yeast-based bioassay. To that end, yeast strains that functionally express the rat somatostatin receptor subtype 2 (SSTR2) were constructed. High-affinity binding sites for somatostatin ([125I-Tyr-11]S-14) comparable to those in native tissues were detected in yeast membrane extracts at levels equivalent to the alpha-mating pheromone receptor (Ste2p). Somatostatin-dependent growth of strains modified by deletion of genes encoding components of the pheromone response pathway was detected through induction of a pheromone-responsive HIS3 reporter gene, enabling cells to grow on medium lacking histidine. Dose-dependent growth responses to S-14 and related SSTR2 subtype-selective agonists that were proportional to the affinity of the ligands for SSTR2 were observed. The growth response required SSTR2, G alpha proteins, and an intact signal transduction pathway. The sensitivity of the bioassay was affected by intracellular levels of the G alpha protein. A mutation in the SST2 gene, which confers supersensitivity to pheromone, was found to significantly enhance the growth response to S-14. In sst2 delta cells, SSTR2 functionally interacted with both a chimeric yeast/mammalian G alpha protein and the yeast G alpha protein, Gpa1p; to promote growth. These yeast strains should serve as a useful in vivo reconstitution system for examination of molecular interactions of the G-protein-coupled receptors and G proteins.


Subject(s)
GTP-Binding Proteins/physiology , Receptors, Somatostatin/physiology , Saccharomyces cerevisiae/physiology , Signal Transduction , Somatostatin/metabolism , Transcription Factors , Animals , Base Sequence , Biological Assay , Cell Division , Cell Membrane/metabolism , DNA Primers/chemistry , Molecular Sequence Data , Pheromones/physiology , Rats , Receptors, Mating Factor , Receptors, Peptide/physiology , Recombinant Proteins , Saccharomyces cerevisiae/growth & development , Somatostatin/chemistry
8.
Biochem Biophys Res Commun ; 216(3): 913-21, 1995 Nov 22.
Article in English | MEDLINE | ID: mdl-7488212

ABSTRACT

To determine which residues within the rat somatostatin receptor subtype SSTR2 may be interacting with the lys9 of somatostatin-14 (S-14), mutant SSTR2 receptors were created by mutating asp89 or asp122. [125I Tyr11]S-14 binding to D89A and D89E mutants suggests that asp89 is not directly involved in S-14 binding. Binding studies with the charge switch mutants, asp9S-14, and D122K, suggest that asp122 may be interacting with the lys9 of S-14. [125I Tyr11]asp9S-14 displayed saturable binding to D122K with an affinity comparable to that seen with [125I Tyr11]S-14 and WT SSTR2. These data suggest that the interaction between lys9 of S-14 and the TM3 asp122 of SSTR2 represents one contact site between S-14 and SSTR2.


Subject(s)
Aspartic Acid/analysis , Cell Membrane/chemistry , Receptors, Somatostatin/chemistry , Receptors, Somatostatin/metabolism , Somatostatin/metabolism , Animals , Aspartic Acid/metabolism , Binding Sites , Binding, Competitive , CHO Cells , Cricetinae , Guanosine 5'-O-(3-Thiotriphosphate)/pharmacology , Hormone Antagonists/metabolism , Mutagenesis, Site-Directed , Peptides, Cyclic/metabolism , Rats , Receptors, Somatostatin/genetics , Structure-Activity Relationship , Transfection , Tyrosine/metabolism
9.
Mol Pharmacol ; 47(1): 82-7, 1995 Jan.
Article in English | MEDLINE | ID: mdl-7838136

ABSTRACT

Four of the five somatostatin receptor (SSTR) subtypes bind the two native forms of somatostatin, i.e., somatostatin-14 (S-14) and amino-terminally extended somatostatin-28 (S-28), with comparable affinities (approximately 0.2 nM). The SSTR5 subtype exhibits 10-50-fold higher affinity for S-28 than for S-14 (0.2 and 5 nM, respectively). To determine which domains in SSTR5 are responsible for the observed pharmacological selectivity, a series of SSTR2/SSTR5 chimeras were constructed and expressed in Chinese hamster ovary cells. Saturation and competition radioligand binding studies demonstrated that the region encompassing transmembrane domain 6 (TM6) through the carboxyl terminus plays a critical role in the lower binding affinity of S-14 for SSTR5. Substitution of this region with the corresponding region of SSTR2 produced chimeric receptors with high affinity for both S-28 and S-14. Examination of amino acid sequences revealed both a specific conserved hydrophobic residue and a conserved tyrosine in TM6 of SSTR1-4. At comparable positions in SSTR5, these residues are glycine (G258) and phenylalanine (F265), respectively. Substitution of G258 with phenylalanine did not alter the preference of SSTR5 for S-28 over S-14. However, substitution of F265 with tyrosine increased the binding affinity of S-14 by 20-fold, to an affinity comparable to that observed for the SSTR2 subtype. These data indicate that replacement of phenylalanine with tyrosine at position 265 in SSTR5 can modify ligand binding selectivity and abolish the preference for S-28 over S-14. This finding suggests that the tyrosine in the predicted TM6 may be an important contact point between somatostatin and SSTR.


Subject(s)
Mutation , Phenylalanine/genetics , Phenylalanine/metabolism , Receptors, Somatostatin/genetics , Receptors, Somatostatin/metabolism , Somatostatin/metabolism , Tyrosine/genetics , Tyrosine/metabolism , Amino Acid Sequence , Animals , Base Sequence , CHO Cells , Cricetinae , DNA, Complementary/genetics , Kinetics , Macromolecular Substances , Molecular Sequence Data , Mutagenesis, Site-Directed , Rats , Receptors, Somatostatin/classification , Recombinant Fusion Proteins/classification , Recombinant Fusion Proteins/metabolism , Sequence Homology, Amino Acid , Structure-Activity Relationship
10.
Biochem J ; 302 ( Pt 2): 397-403, 1994 Sep 01.
Article in English | MEDLINE | ID: mdl-8092990

ABSTRACT

The expression of beta 2-adrenergic receptors is up-regulated by glucocorticoids. In contrast, beta 1-adrenergic receptors display glucocorticoid-induced down-regulation. In rat C6 glioma cells, which express both of these subtypes of beta-adrenergic receptors, the synthetic glucocorticoid dexamethasone stimulates no change in the total beta-adrenergic receptor content, but rather shifts the beta 1:beta 2 ratio from 80:20 to 50:50. Radioligand binding and immunoblotting demonstrate a sharp decline in beta 1-adrenergic receptor expression. Metabolic labelling of cells with [35S]-methionine in tandem with immunoprecipitation by beta 1-adrenergic-receptor-specific antibodies reveals a sharp decline in the synthesis of the receptor within 48 h for cells challenged with glucocorticoid. Steady-state levels of beta 1-adrenergic-receptor mRNA declined from 0.47 to 0.26 amol/microgram of total cellular RNA within 2 h of dexamethasone challenge, as measured by DNA-excess solution hybridization. The stability of receptor mRNA was not influenced by glucocorticoid; the half-lives of the beta 1- and beta 2-subtype mRNAs were 1.7 and 1.5 h respectively. Nuclear run-on assays revealed the basis for the down-regulation of receptor expression, i.e. a sharp decline in the relative rate of transcription for the beta 1-adrenergic-receptor gene in nuclei from dexamethasone-treated as compared with vehicle-treated cells. These data demonstrate transcriptional suppression as a molecular explanation for glucocorticoid-induced down-regulation of beta 1-adrenergic receptors.


Subject(s)
Dexamethasone/pharmacology , Gene Expression Regulation/drug effects , Receptors, Adrenergic, beta/genetics , Animals , Base Sequence , Cricetinae , Down-Regulation/drug effects , Electrophoresis, Polyacrylamide Gel , Glioma , Immunoblotting , Molecular Sequence Data , Nucleic Acid Hybridization , Precipitin Tests , RNA, Messenger/genetics , RNA, Messenger/metabolism , Radioligand Assay , Rats , Receptors, Adrenergic, beta/drug effects , Transcription, Genetic/drug effects , Tumor Cells, Cultured
11.
Mol Pharmacol ; 45(3): 410-6, 1994 Mar.
Article in English | MEDLINE | ID: mdl-8145728

ABSTRACT

The pharmacology, signal transduction, and coupling to G proteins of the rat somatostatin (SRIF) receptor (SSTR)1 have been characterized in transfected Chinese hamster ovary (CHO) (K1 strain) cells. The expressed receptor exhibited saturable, high affinity binding of several radioiodinated SRIF analogues. Three different radioligands were used to determine the pharmacological properties of this SSTR subtype. [125I-Tyr11]SRIF-14 (125I-S-14), [Leu8,D-Trp22,125I-Tyr25]SRIF-28 (125I-S-28), and cyclo(D-Trp-Lys-Abu-Phe-MeAla-125I-Tyr) (125I-peptide C) displayed the following rank order of affinity (Kd) for the SSTR1 subtype: 125I-S-14 > or = 125I-S-28 > 125I-peptide C. Competition of 125I-S-14 with S-14, S-28, or peptide C displayed the same rank order of potency. Chemical cross-linking of specifically bound 125I-S-28 to membranes from CHO cells expressing the receptor indicated that the molecular weight of the SSTR1 expressed in CHO cells is approximately 70,000, suggesting that it is heavily glycosylated. Previous reports have suggested that the human SSTR1 [Mol. Pharmacol. 42:28-34 (1992)] couples poorly to G proteins. The coupling of the rat SSTR1 to G proteins was demonstrated by three independent methods. (a) Binding of 125I-S-14 to the SSTR1 subtype was inhibited in a dose-dependent fashion by incubation of membranes with guanosine-5'-O-(3-thio)triphosphate. (b) Treatment of cells with pertussis toxin decreased binding by 80%. (c) Immunoprecipitation of 125I-S-14 binding was observed with antiserum specific for Gi alpha 1,2, but not with antiserum specific for Gs alpha, in membranes from transfected cells. In CHO cells transfected with the SSTR1 cDNA, SRIF inhibited forskolin-stimulated cAMP accumulation by up to 50%, in a dose-dependent fashion (ED50 = 1.1 nM). Pertussis toxin treatment decreased both the efficacy and the potency of the SRIF-mediated inhibition of cAMP accumulation (from 50% to 22%), compared with control untreated cells. These data suggest that the rat SSTR1 inhibits cAMP accumulation by coupling to pertussis toxin-sensitive G proteins.


Subject(s)
Cyclic AMP/antagonists & inhibitors , GTP-Binding Proteins/metabolism , Receptors, Somatostatin/metabolism , Amino Acid Sequence , Animals , Base Sequence , CHO Cells , Cricetinae , Cyclic AMP/metabolism , Guanosine 5'-O-(3-Thiotriphosphate)/pharmacology , Molecular Sequence Data , Rats , Receptors, Somatostatin/drug effects , Receptors, Somatostatin/genetics
12.
Biochem Biophys Res Commun ; 191(3): 968-76, 1993 Mar 31.
Article in English | MEDLINE | ID: mdl-8096694

ABSTRACT

The rat somatostatin receptor SSTR2 subtype has been cloned and expressed in Chinese Hamster Ovary (CHO) cells. Four different radioligands were used to determine the pharmacological properties of this somatostatin receptor subtype. [125ITyr11]S-14, [125ITyr25]S-28, and cyclo (D-Trp-Lys-Abu-Phe-MeAla-[125ITyr]) displayed comparable affinities for the SSTR2 subtype (approximately 100 pM). The affinity of a fourth radioligand, D-beta Nal-cyclo (Cys-[125ITyr]-DTrp-Lys-Val-Cys)-Thr-H2N, was approximately 10-fold lower (approximately 1000 pM) than the three other radioligands. Competition of [125I]S-14 with either S-14 or S-28 also revealed comparable IC50 values (250 pM). In CHO cells transfected with the SSTR2 cDNA, S-14 inhibited forskolin-stimulated cAMP accumulation by 75% in a dose-dependent fashion (EC50 = 350 pM).


Subject(s)
Cyclic AMP/metabolism , Receptors, Somatostatin/physiology , Animals , Base Sequence , CHO Cells , Cloning, Molecular , Cricetinae , DNA/genetics , Guanosine 5'-O-(3-Thiotriphosphate)/metabolism , Kinetics , Molecular Sequence Data , Oligodeoxyribonucleotides/chemistry , Polymerase Chain Reaction , Rats , Somatostatin/metabolism , Transfection
13.
J Neurochem ; 60(1): 1-9, 1993 Jan.
Article in English | MEDLINE | ID: mdl-8417134

ABSTRACT

Study of transmembrane signaling via G proteins has focused to a large extent upon investigations of individual G protein-linked receptor-effector systems. Agonist-induced desensitization and down-regulation of beta-adrenergic receptors, for example, have been studied extensively and adopted as a general model for G protein-linked receptor regulation. This review focuses not only on agonist regulation of adrenergic receptor gene expression, but also on how agonists regulate opposing adrenergic receptor-mediated pathways. This important feature of G protein-mediated pathways, i.e., cross-regulation and integration of information among several pathways, will be discussed in the context of what has been learned in the adrenergic receptor-coupled pathways.


Subject(s)
GTP-Binding Proteins/physiology , Gene Expression Regulation , Receptors, Adrenergic/physiology , Adenylyl Cyclase Inhibitors , Adenylyl Cyclases/metabolism , Animals , Humans , Stimulation, Chemical , Type C Phospholipases/metabolism
14.
J Biol Chem ; 267(36): 26017-22, 1992 Dec 25.
Article in English | MEDLINE | ID: mdl-1281480

ABSTRACT

Protein kinases play a pivotal role in the propagation and modulation of transmembrane signaling pathways. Two major classes of receptors, G-protein-linked and tyrosine kinase receptors not only propagate signals but also are substrates for phosphorylation in response to stimulation by agonist ligands. Insulin (operating via tyrosine kinase receptors) and catecholamines (operating by G-protein-linked receptors) are counterregulatory with respect to lipid and carbohydrate metabolism. How, on a cellular level, these two distinct classes of receptors may cross-regulate each other remains controversial. In the present work we identify a novel cross-talk between members of two distinct classes of receptors, tyrosine kinase (insulin) and G-protein-linked (beta-adrenergic) receptors. Treatment of DDT1 MF-2 hamster vas deferens smooth muscle cells with insulin promoted a marked attenuation (desensitization) of beta-adrenergic receptor-mediated activation of adenylylcyclase. Measured by immune precipitation of beta 2-adrenergic receptors from cells metabolically labeled with [32P]orthophosphate, the basal state of receptor phosphorylation was increased 2-fold by insulin. Phosphoamino acid analysis revealed that for insulin-stimulated cells, the beta 2-adrenergic receptors showed increased phosphorylation on tyrosyl and decreased phosphorylation on threonyl residues. Phosphorylation of the beta-adrenergic receptor was rapid and peaked at 30 min following stimulation of cells by insulin. beta-Adrenergic receptor phosphorylation and attenuation of catecholamine-sensitive adenylylcyclase provide a biochemical basis for the counterregulatory effects of insulin upon catecholamine action.


Subject(s)
GTP-Binding Proteins/metabolism , Insulin/pharmacology , Isoproterenol/pharmacology , Protein-Tyrosine Kinases/metabolism , Receptors, Adrenergic, beta/metabolism , Animals , Cell Line , Cricetinae , Iodine Radioisotopes , Kinetics , Male , Phosphates/metabolism , Phosphorylation , Phosphoserine/analysis , Phosphothreonine/analysis , Phosphotyrosine , Receptor, Insulin , Receptors, Adrenergic, beta/drug effects , Tyrosine/analogs & derivatives , Tyrosine/analysis , Vas Deferens
15.
J Biol Chem ; 267(12): 8468-72, 1992 Apr 25.
Article in English | MEDLINE | ID: mdl-1314828

ABSTRACT

Cross-regulation from the stimulatory to the inhibitory adenylylcyclase pathways has been described (Hadcock, J. R., Ros, M., Watkins, D. C., and Malbon, C. C. (1990) J. Biol. Chem. 265, 14784-14790). More recently, persistent activation (48 h) of the inhibitory adenylylcyclase pathway has been shown to cross-regulate the stimulatory pathway (i) enhancing the maximal response of beta-adrenergic agonits, (ii) increasing the expression of beta-adrenergic receptor, and (iii) reducing the ED50 for the isoproterenol-stimulated response by 50-fold (Hadcock, J. R., Port, J. D., and Malbon, C. C. (1991) J. Biol. Chem. 266, 11915-11922). Here, we report that short term activation (60 min) of the inhibitory adenylylcyclase pathway of hamster smooth muscle DDT1MF-2 cells with the A1-adenosine receptor agonist N6-phenylisopropyladenosine (PIA) likewise enhances the stimulatory adenylylcyclase response to the beta-adrenergic agonist isoproterenol. The PIA effect was exerted at the level of the receptor, i.e., the beta-adrenergic receptor-mediated response was enhanced, whereas the guanosine 5'-O-(thiotriphosphate)- and forskolin-stimulated adenylylcyclase activities were largely unaffected. In contrast to longer term persistent activation of the inhibitory pathway, receptor number and affinity for 125I-labeled cyanopindolol were unaffected. Metabolic labeling of cells with [32P]orthophosphate and immuneprecipitation of beta-adrenergic receptors detected phosphorylation of the receptor in unstimulated cells and marked phosphorylation in cells challenged with epinephrine. When cells were challenged short term with PIA, the basal state of beta-adrenergic receptor phosphorylation was reduced by 75%. Treating cells with PIA in combination with the cAMP analog 8-(4-chlorophenylthio)adenosine cyclic AMP attenuated the enhanced receptor-mediated adenylylcyclase response observed in cells treated with PIA alone. These data suggest that short term cross-regulation from the inhibitory to stimulatory adenylylcyclase pathways results in the following: (i) decreased intracellular cAMP levels and protein kinase A activity, (ii) reduced phosphorylation of the beta 2-adrenergic receptor in the "basal" (i.e. unstimulated) state, and (iii) enhanced receptor-mediated activation of Gs.


Subject(s)
Adenylyl Cyclases/metabolism , GTP-Binding Proteins/metabolism , Receptors, Adrenergic, beta/metabolism , Animals , Cells, Cultured , Colforsin/pharmacology , Cricetinae , Cyclic AMP/pharmacology , Enzyme Activation , Epinephrine/pharmacology , Guanosine 5'-O-(3-Thiotriphosphate)/pharmacology , Phosphorylation , Protein Kinases/metabolism , Radioligand Assay
16.
Endocrinology ; 129(2): 1116-8, 1991 Aug.
Article in English | MEDLINE | ID: mdl-1649740

ABSTRACT

Steady state levels of the mRNAs for alpha 1B, beta 1- and beta 2-adrenergic receptors (alpha 1BAR, beta 1AR, beta 2AR) were quantified by DNA excess solution hybridization assays in the heart, lungs, and liver of rats. Tissues for RNA extraction were obtained from euthyroid and thyroidectomized rats and from thyroidectomized rats treated with a single dose of thyroxine. Thyroidectomy resulted in significant decreases in beta 1AR and beta 2AR mRNAs in heart and lung and alpha 1BAR mRNA in liver, whereas the levels of beta 2AR mRNA in liver and alpha 1BAR mRNA in heart and lung were significantly increased. All these changes were reversed within 20 hours of a single s.c. injection of 1 mg/kg thyroxine. These findings indicate for the first time that thyroid state regulates mRNA levels for adrenergic receptors, and that this regulation is tissue- and receptor-specific. The changes in adrenergic receptor mRNAs correlate with and probably underlie the well documented, thyroid-dependent changes in the cellular densities and physiological reactivities of adrenergic receptors.


Subject(s)
Gene Expression Regulation , Hypothyroidism/metabolism , RNA, Messenger/metabolism , Receptors, Adrenergic, alpha/genetics , Receptors, Adrenergic, beta/genetics , Animals , Gene Expression Regulation/drug effects , Liver/metabolism , Lung/metabolism , Male , Myocardium/metabolism , Nucleic Acid Hybridization , Organ Specificity , Rats , Rats, Inbred Strains , Thyroidectomy , Thyroxine/pharmacology
17.
Trends Neurosci ; 14(6): 242-7, 1991 Jun.
Article in English | MEDLINE | ID: mdl-1716018

ABSTRACT

The molecular cloning of certain members of several distinct classes of receptors has opened up new avenues by which the regulation of signal-transducing proteins can be investigated. The information derived from molecular cloning permits not only studies of functional domains via mutagenesis, but also the study of gene regulation and the cell biology of these receptors by the use of molecular probes. All receptors are bifunctional, possessing domains for ligand binding as well as for signal propagation through binding to other protein(s), DNA or ion channels. Regulation of receptor expression and function in response to agonist stimulation is a central feature of receptor biology. In this article, Drs Hadcock and Malbon focus on the regulation of receptor expression by agonists at the transcriptional and post-transcriptional levels. Regulation of the expression of three classes of receptors central to neurobiology is highlighted: namely, steroid hormone receptors (estrogen receptor), G protein-coupled receptors (beta2-adrenergic receptor) and tyrosine kinase receptors (epidermal growth factor receptor). The emerging idea of cross regulation between receptors is also discussed in order to demonstrate the complexities of studying receptor expression.


Subject(s)
Receptors, Drug/genetics , Transcription, Genetic/drug effects , Animals , Gene Expression Regulation/drug effects , Humans , Receptors, Drug/drug effects
18.
J Biol Chem ; 266(18): 11915-22, 1991 Jun 25.
Article in English | MEDLINE | ID: mdl-1646818

ABSTRACT

Cross-regulation from the stimulatory (Gs alpha)-mediated) to the inhibitory (Gi alpha-mediated) pathways controlling adenylylcyclase has been described (Hadcock, J. R., Ros, M., Watkins, D. C., and Malbon, C. C. (1990) J. Biol. Chem. 265, 14784-14790). The extent to which cross-regulation occurs from inhibitory to stimulatory pathways for adenylylcyclase was explored. Persistent activation of the inhibitory pathway of adenylylcyclase by the A1-adenosine receptor agonist (-)-N6 (R-phenylisopropyl) adenosine (PIA) in hamster smooth muscle DDT1 MF-2 cells enhanced the stimulatory pathway of adenylylcyclase and its activation by the beta 2-adrenergic receptor agonist isoproterenol. PIA treatment (48 h) of cells increased isoproterenol-stimulated adenylylcyclase by 2-fold. In addition, the ED50 for stimulation of adenylylcyclase by isoproterenol decreased 50-fold to approximately 1 nM. Persistent activation of cells with PIA increased beta 2-adrenergic receptor number in a time- and dose-dependent manner. The steady-state levels of beta 2-adrenergic receptors (radioligand binding and immunoblotting) and receptor mRNA levels increased by more than 70%, while the half-life of the receptor (24 h) was unaltered. Both A1-adenosine receptor binding and Gi alpha 2 levels declined by half in cells persistently activated with PIA. Although Gi alpha 2 mRNA levels and the relative rate of synthesis of Gi alpha 2 protein upon persistent activation of the inhibitory pathway were found to increase, a decrease in the half-life of Gi alpha 2 from approximately 75 h in naive cells to approximately 40 in cells provides the basis for the decline in Gi alpha 2 levels. The steady-state level of mRNA and half-life of Gs alpha protein were unaltered in persistently activated cells. Thus, activation of the inhibitory pathway of adenylylcyclase cross-regulates the stimulatory, hormone-sensitive adenylylcyclase system by: (i) up-regulating beta 2-adrenergic receptors and enhancing the activation of the stimulatory adenylylcyclase pathway and (ii) down-regulating elements of the inhibitory adenylylcyclase pathway (Gi alpha 2 and A1-adenosine receptor binding).


Subject(s)
Adenylyl Cyclases/metabolism , GTP-Binding Proteins/metabolism , Receptors, Adrenergic, beta/metabolism , Adenosine/metabolism , Adenylyl Cyclase Inhibitors , Animals , Blotting, Western , Cells, Cultured , Cricetinae , Cross Reactions , Down-Regulation , Electrophoresis, Polyacrylamide Gel , Enzyme Activation , Isoproterenol/pharmacology , Phenylisopropyladenosine/pharmacology , Precipitin Tests , RNA, Messenger/metabolism , Radioligand Assay , Receptors, Adrenergic, beta/drug effects , Up-Regulation
19.
J Biol Chem ; 266(4): 2233-8, 1991 Feb 05.
Article in English | MEDLINE | ID: mdl-1846620

ABSTRACT

Stimulation of DDT1 MF-2 vas deferens cells with epinephrine resulted in a time- and dose-dependent loss of alpha 1-adrenergic receptor-specific ligand binding. Regulation of alpha 1-adrenergic receptor mRNA was characterized. In monolayer culture, cells displayed 0.7 +/- 0.05 amol of alpha 1-adrenergic receptor mRNA/microgram of total cellular RNA. Epinephrine, which acts at both alpha 1- and beta 2-adrenergic receptors of DDT1 MF-2 cells, induced a short term (2-8 h) increase (50-70%) in the abundance of alpha 1-adrenergic receptor mRNA. Propranolol, a beta 2-adrenergic receptor antagonist, attenuated the epinephrine-mediated increase in alpha 1-adrenergic receptor mRNA but did not affect the decrease in alpha 1-adrenergic receptor-specific ligand binding. Phentolamine, an alpha 1-adrenergic receptor antagonist, did not attenuate the epinephrine-mediated increase in alpha 1-adrenergic receptor mRNA at 4 h but did block the decrease in alpha 1-adrenergic receptor-specific ligand binding. The half-life of the alpha 1-adrenergic receptor mRNA was approximately 7 h in untreated cells as well as in cells challenged with epinephrine. The epinephrine-promoted increase in alpha 1-adrenergic receptor mRNA was found to result from cross-regulation via beta 2-adrenergic receptors. Cholera toxin, forskolin, as well as the cyclic AMP analog CPT cAMP (8-(4-chlorophenylthio)adenosine 3':5'-cyclic monophosphate) increased the alpha 1-adrenergic receptor mRNA at 4 h, as did epinephrine in the presence of alpha 1-antagonists but not in the presence of a beta-adrenergic antagonist. This is the first report of heterologous up-regulation of mRNA levels of adrenergic receptors. Cross-regulation between alpha 1- and beta 2-adrenergic receptor-mediated pathways at 4 h occurs at the level of mRNA whereas later down-regulation of alpha 1-receptor mRNA and binding proceed via agonist activation of alpha 1-adrenergic receptors.


Subject(s)
GTP-Binding Proteins/metabolism , RNA, Messenger/metabolism , Receptors, Adrenergic, alpha/genetics , Animals , Blotting, Northern , Cell Line , Cholera Toxin/pharmacology , Colforsin/pharmacology , Cricetinae , Cyclic AMP/analogs & derivatives , Cyclic AMP/pharmacology , Epinephrine/pharmacology , Male , Phentolamine/pharmacology , Propranolol/pharmacology , Receptors, Adrenergic, alpha/metabolism , Thionucleotides/pharmacology , Vas Deferens/metabolism
20.
Int J Biochem ; 23(1): 7-20, 1991.
Article in English | MEDLINE | ID: mdl-1850702

ABSTRACT

1. G-protein-linked transmembrane signaling has emerged as a major pathway for information transduction across the cell membrane. 2. In addition to photopigments that propagate the signal from light, cell-surface receptors for hormones, neurotransmitters, and autacoids propagate signals from ligand binding to membrane-bound effector units via G-proteins. 3. Biochemical and molecular features of one prominent member of these receptors, the beta-adrenergic receptor, will be highlighted in the present article. 4. The role of the human epidermoid carcinoma A431 cells as a model for the study of the structure and biology of beta-adrenergic receptors will be emphasized. 5. A model for receptor regulation, gleaned from recent advances in the biochemistry, cell and molecular biology of beta-adrenergic receptors, is discussed.


Subject(s)
Epidermal Cyst/metabolism , Receptors, Adrenergic, beta/metabolism , Signal Transduction , Amino Acid Sequence , Animals , Cricetinae , GTP-Binding Proteins/metabolism , Humans , Molecular Sequence Data , Protein Conformation , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...